Abstract:Although NCCN guideline does not recommend adjuvant therapy after R0 resection for esophageal carcinoma, the reported recurrence rate of pathologic T2-3N0M0 esophageal patients varies between 41.6% and 51.8%, local regional recurrence rate reaches about 33.3%. Researches show postoperative radiotherapy could increase 5 year overall survival by 5.5%-8.0%. Our previous study has shown postoperative radiotherapy significantly increase 5-year OS (66.3% vs. 58.5%) and DFS (57.4% vs. 47.1%) compared with surgery alone. We launched this prospective, phase III, randomized controlled study primarily to explore the efficacy of postoperative radiotherapy in pathologic T2-3N0M0 thoracic esophageal squamous cell carcinoma patients. We randomly assigned R0 resection patients to surgery alone or to receive postoperative radiotherapy (IMRT) of 50.4 Gy in supraclavicular field and 56 Gy in mediastinal field (divided by upper rim of clavicular head) in 28 fractions over 5 weeks. Irradiation field was defined from cricothyroid membrane to 3 cm below carina (upper) or tumor bed (middle or lower), which involves 1, 2, 3, 4, 7, part 8 and 10L mediastinal lymph nodes. The primary endpoint was disease free survival. The secondary endpoint was local regional recurrence rate, overall survival, and toxicities. All analyses were done by intention-to-treat. The study is registered with ClinicalTrials.gov, number NCT01745107. From October 2012 to May 2017, 158 patients were enrolled in this study, 78 were assigned to surgery alone and 80 to postoperative radiotherapy. Baseline characteristics were well balanced between two groups, and 88.8% patients in postoperative radiotherapy group received radiotherapy. Median follow-up time is 35.6 months. To calculate survival time, we included 136 patients who were followed up more than 1 year except for that died within 1 year. Significant increases were seen in 1 and 2-year disease-free survival rate: 85.7%, 79.8% in postoperative radiotherapy group and 78.8%, 64.6% in surgery group (HR = 0.52; 95% CI = 0.28-0.97; P = 0.039). Whereas the 1, 2 year overall survival were not significantly different (95.7%, 91.1% in radiotherapy group vs. 95.5%, 90.7% in surgery group, P = 0.197). The overall recurrence rate was 29.4%. Local regional recurrence rate was significantly decreased in radiotherapy group (11.4% vs. 34.8% in surgery group, P = 0.001), while distant metastasis were not significant different between two groups (10.0% in radiotherapy group vs. 12.1% in surgery group, P = 0.693). Grade 3 toxicity rate associated with radiotherapy was 9.4%; no grade 4 or 5 toxicities were showed. Postoperative radiotherapy increased disease free survival and decreased local regional recurrence rate, in pathological T2-3N0M0 thoracic esophageal squamous cell carcinoma patients. No severe adverse events were showed. Further enrollment and follow-up are warranted to validate these findings in this ongoing trial.

Postoperative tumor bed radiation versus T-shaped field radiation in the treatment of locally advanced thoracic esophageal squamous cell carcinoma: a phase IIb multicenter randomized controlled trial

Postoperative Radiotherapy Involving Tumor Bed with or Without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial

Phase III Randomized Study of Preoperative Versus Postoperative Chemoradiotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB–III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial

Preliminary Evaluation of Postoperative Radiotherapy with Small T-shaped Field in Thoracic Esophageal Squamous Cell Carcinoma.

Randomized phase II trial comparing tumor bed alone with tumor bed and elective nodal postoperative radiotherapy in patients with locoregionally advanced thoracic esophageal squamous cell carcinoma.

Prognostic Impact of Postoperative Radiation in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Cancer

Postoperative Radiotherapy in Curatively Resected Esophageal Squamous Cell Carcinoma With Occult Recurrent Laryngeal Nerve Lymph Node Metastasis

A Retrospective Study to Investigate the Pattern of Local Regional Failure after Different Surgical Approaches for Thoracic Esophageal Squamous Cancer: Should the Target Volume of Postoperative Radiation Therapy Differ for Different Surgical Approaches?

Recommendation for the Definition of Postoperative Radiotherapy Target Volume Based on a Pooled Analysis of Patterns of Failure after Radical Surgery among Patients with Thoracic Esophageal Squamous Cell Carcinoma.

Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial

The Prognosis and Feasibility of Extensive Clinical Target Volume in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

Preliminary Evaluation of Postoperative Radiotherapy between Small T-Shaped Field and All Regional Lymph Nodes Field in Thoracic Esophageal Squamous Cell Carcinoma

Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

Postoperative Intensity Modulated Radiation Therapy Improved Survival of Lymph Node-Positive or Stage III Squamous Cell Carcinoma Esophagus

Postoperative Radiation Therapy in Pathologic T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase 3, Randomized Controlled Study

Patterns of Failure after Radical Surgery among Patients with Thoracic Esophageal Squamous Cell Carcinoma: Implications for the Clinical Target Volume Design of Postoperative Radiotherapy.

Delayed Postoperative Radiotherapy Might Improve the Long-Term Prognosis of Locally Advanced Esophageal Squamous Cell Carcinoma

Propensity-matched study on locally advanced esophageal cancer: surgery versus post-operative radiotherapy

Difference in Failure Patterns of Pt3-4N0-3m0 Esophageal Cancer Treated by Surgery Vs Surgery Plus Radiotherapy

A Phase III Clinical Trial of Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus.